Related Experiment Video
Updated: Dec 12, 2025
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.9K
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Dhanusha A Nalawansha1, Craig M Crews2
1Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT 06511, USA.
Cell Chemical Biology
|August 16, 2020
Summary
Targeted protein degradation (TPD) utilizes PROteolysis TArgeting Chimeras (PROTACs) to eliminate disease-causing proteins. This review explores PROTAC advantages, regulation, and novel E3 ligases for advancing precision medicine.
Area of Science:
- Chemical Biology
- Drug Discovery
- Molecular Biology
Background:
- Targeted protein degradation (TPD) represents a significant advancement in drug discovery.
- PROteolysis TArgeting Chimeras (PROTACs) leverage the ubiquitin-proteasome system for targeted protein elimination.
- Recent research highlights PROTACs' unique mechanism and therapeutic potential, driving academic and industrial interest.
Purpose of the Study:
- To review the advantages of PROTAC technology.
- To discuss the spatiotemporal regulation of protein degradation.
- To explore current and novel E3 ligases for expanding TPD applications.
Main Methods:
- Literature review of PROTAC technology and its applications.
- Analysis of the ubiquitin-proteasome system in targeted protein degradation.
- Exploration of chemically tractable E3 ligases and their role in TPD.
Main Results:
- PROTACs offer distinct advantages over traditional therapeutics.
- Spatiotemporal control of protein degradation is crucial for therapeutic efficacy.
- Expanding the E3 ligase repertoire is key to unlocking TPD's full potential.
Conclusions:
- PROTAC technology is a promising new modality for precision medicine.
- Further research into E3 ligases will enhance the development of TPD therapeutics.
- Targeted protein degradation offers a novel strategy for treating various diseases.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
02:57Targeted Cancer Therapies
8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.5K
01:16Therapeutic Drug Monitoring: Overview and Classification
159
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
159
01:26Targets for Drug Action: Overview
9.7K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.7K
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.6K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.6K